Estrogen, cytokines, and pathogenesis of postmenopausal osteoporosis
The DOI matches its Crossref record; 90 of the 90 references it cites were found in a registry or an index.
Abstract
In summary, available data demonstrate that IL-1 and TNF are the causative agents underlying the bone loss induced by estrogen deficiency. Indeed, these factors are produced in bone and the bone marrow, released in larger amounts from cells of estrogen-deficient subjects, and indispensable for reproducing the effects of estrogen deficiency in bone. These observations support the hypothesis that the bone sparing effect of estrogen is due to the ability of the hormone to block osteoclastogenesis, the activation of mature osteoclasts and, as recently demonstrated, the rate of apoptotic osteoclast death. Although IL-1 and TNF play a prominent causal role in these events, the bone-sparing effect of estrogen is mediated by numerous cytokines which, by simultaneously stimulating multiple target cells, induce effects that are not accounted for by any one single factor (Fig. 2). The ability of estrogen to regulate some, but not all, the cytokines involved in this process is not inconsistent with this hypothesis because cytokines have potent synergistic effects. Thus, a considerable increase in bone resorption may result from a relatively small increase in the concentration of only a few of the bone-resorbing factors present in the bone microenvironment. This concept is best illustrated by the study of Miyaura et al. demonstrating that the concentrations of either IL-1, IL-6, IL-6 receptor, or prostaglandins detected in the bone marrow of OVX mice are insufficient to account for the increased bone resorption caused by estrogen withdrawal. In contrast, the increase in bone resorption induced by OVX can be explained by the cumulative effects of these cytokines. Thus, a better understanding of the cooperative effects of cytokines and a recognition that the contribution of individual cytokines to postmenopausal bone loss varies with the passage of time after menopause are necessary to fully understand the mechanism of action of estrogen in bone. Although the relevance of individual bone-targeting cytokines in species specific, the development of transgenic mice with activatable or deactivatable promoters is likely to result in a further clarification of the integrated action of estrogen-regulated cytokines in human bone cells and lay the foundations for the use of cytokine inhibitors in the treatment of postmenopausal osteoporosis.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Estrogen acts via suppression of bone resorption [43–45]”
From The Effect of Tobacco Smoking on Bone Mass: An Overview of Pathophysiologic Mechanisms (2018) · cites this paper as [44]
In the citing paper
“In addition, estrogen inhibits osteoclast formation by reducing the levels of other osteoclastogenic cytokines such as IL-1, IL-6, IL-11, TNF-α, TNF-β, and M-CSF [160, 161].”
From Biology of Bone Tissue: Structure, Function, and Factors That Influence Bone Cells (2015) · cites this paper as [160]
Citations
Cites
Interleukin-1 and interleukin-1 antagonism
Dinarello, C. (1991) · Blood · doi:10.1182/blood.v77.8.1627.1627 · Cited by 2,304
Yoshida, H., Hayashi, S.-I., Kunisada, T., Ogawa, M., Nishikawa, S., Okamura, H., Sudo, T., Shultz, L. D., & Nishikawa, S.-I. (1990) · Nature · doi:10.1038/345442a0 · Cited by 1,789
Increased Osteoclast Development After Estrogen Loss: Mediation by Interleukin-6
Jilka, R. L., Hangoc, G., Girasole, G., Passeri, G., Williams, D. C., Abrams, J. S., Boyce, B., Broxmeyer, H., & Manolagas, S. C. (1992) · Science · doi:10.1126/science.1621100 · Cited by 1,442
Bertolini, D. R., Nedwin, G. E., Bringman, T. S., Smith, D. D., & Mundy, G. R. (1986) · Nature · doi:10.1038/319516a0 · Cited by 1,434
Bisphosphonates promote apoptosis in murine osteoclasts in vitro and in vivo
Hughes, D. E., Wright, K. R., Uy, H. L., Sasaki, A., Yoneda, T., Roodman, D. G., Mundy, G. R., & Dr. Boyce, B. F. (1995) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.5650101008 · Cited by 1,040
An interleukin 1 like factor stimulates bone resorption in vitro
Gowen, M., Wood, D. D., Ihrie, E. J., McGuire, M. K. B., & Russell, R. G. G. (1983) · Nature · doi:10.1038/306378a0 · Cited by 1,012
Modulation of Osteoclast Differentiation
SUDA, T., TAKAHASHI, N., & MARTIN, T. J. (1992) · Endocrine Reviews · doi:10.1210/edrv-13-1-66 · Cited by 1,004 · cited 2×
“(22) These mice, which are cured by the administration of M-CSF,(3s) have an extra thymidine inserted within the coding region of the M-CSF gene, a mutation that generates a stop codon within the coding sequence,(3h) thereby resulting in the production of a defective M-CSF.(22) The formation of osteoclasts in bone mar…”
BackgroundSoluble interleukin-6 receptor triggers osteoclast formation by interleukin 6.
Tamura, T., Udagawa, N., Takahashi, N., Miyaura, C., Tanaka, S., Yamada, Y., Koishihara, Y., Ohsugi, Y., Kumaki, K., & Taga, T. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.24.11924 · Cited by 825
TURNER, R. T., RIGGS, B. L., & SPELSBERG, T. C. (1994) · Endocrine Reviews · doi:10.1210/edrv-15-3-275 · Cited by 754
Interleukin-6 deficient mice are protected from bone loss caused by estrogen depletion.
Poli, V., Balena, R., Fattori, E., Markatos, A., Yamamoto, M., Tanaka, H., Ciliberto, G., Rodan, G. A., & Costantini, F. (1994) · The EMBO Journal · doi:10.1002/j.1460-2075.1994.tb06368.x · Cited by 749
Research works printed but not linked: 11
- Srivastava, 1995, Estrogen down-regulates the expression of M-CSF mRNA in bone marrow stromal cells by stimulating the production of the transcription factor EGR-1, J Bone Miner Res, 10, S18
- Matayoshi, 1995, Generation of human osteoclasts from peripheral blood cd 34+ cells, J Bone Miner Res, 10
- Pacifici, 1990, TNFα and GM-CSF secretion from human blood monocytes: Effect of menopause and estrogen replacement, J Bone Miner Res, 5, 145
- Kimble, 1996, Estrogen inhibits IL-1 and TNF gene expression in transfected murine macrophagic cells, J Bone Miner Res, 11
- Kaneki, 1991, The effect of menopause on IL-1 and IL-6 release from peripheral blood monocytes, J Bone Miner Res, 6, 76
- Thompson, 1991, IL-lra: Properties and uses of an interleukin-1 receptor antagonist, Agents Actions, 41
- Girasole, 1995, Increased serum soluble interleukin-6 receptor levels are induced by ovariectomy, prevented by estrogen replacement, and reversed by alendronate administration, J Bone Miner Res, 10, A86
- McKane, 1993, Effect of age and menopause on serum interleukin-1β and intereleukin-6- levels in women, J Bone Miner Res, 8, 162A
- Kimble, 1994, Long-term treatment with IL-1 receptor antagonist (IL-lra) blocks bone loss in ovariectomized rats, J Bone Miner Res, 9, B380
- Kimble, 1995, Inhibition of IL-6 activity is genetically normal mice does not prevent ovariectomy-induced bone loss, J Bone Miner Res, 10, s160
- Ammann, 1995, Transgenic mice expressing high levels of soluble tumor necrosis factor receptor-1 fusion protein are protected from bone loss caused by estrogen deficiency, J Bone Miner Res, 10
Cited by
Items 701–743 of 743
Arnold, K. K. (2016) · OhioLink ETD Center (Ohio Library and Information Network)
Arias-Herrera, S. (2017) · LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas)
Romualdo, P. C. (2018) · Digital Library of Theses and Dissertations (Universidade de São Paulo) · doi:10.11606/t.58.2018.tde-30082017-101105
Analysis of Estrogen Effects on Eruption of Rat Molars
de Lima-Pansini, L. F., Nayra de Souza Carvalho, L. I. M. A., Guss, N. O., Alves, I. S. S., da Gama-de-Souza, L. N., Graceli, J. B., Pacheco, M. D. S., & Coburn, K. L. A. (2019) · International journal of odontostomatology · doi:10.4067/s0718-381x2019000400418
“Important molecules—such as interleukin-1 alpha (IL-1α); tumour necrosis factor alpha (TNF-α); colony stimulating factor-1 (CSF-1); receptor activator of nuclear factor kappa β (RANK) and its ligand, the receptor activator of nuclear factor kappa β (RANKL); and osteoprotegerin (OPG), a competitor of RANK—are essential…”
BackgroundMethoden zur Entspannung, Schmerzlinderung und Bewusstseinserweiterung
Wallnöfer, H., Walter, H., Crevenna, R., Krenner, L., Singer, M., Hannemann, J., Ott, M., & Schubert, C. (2019) · Springer eBooks · doi:10.1007/978-3-662-48879-9_37
Yang, S. (2019) · Biomedical Journal of Scientific & Technical Research · doi:10.26717/bjstr.2019.23.003933
“These factors can lead to the increase of both osteoclastogenesis and osteoclast activity, eventually causing decreased bone mass and increased risk for osteoporosis [2].”
BackgroundThe Role of Bone Turnover Markers in the Follow up of the Treatment of Osteoporosis
Akisin, N. Y. A., & Ayrı, A. A. (2020) · Journal of Health, Medicine and Nursing · doi:10.7176/jhmn/80-14
Rezende, R. B., & Rabi, L. T. (2022) · Research Society and Development · doi:10.33448/rsd-v11i1.24356
Menopause and care of the mature woman
Lobo, R. A. (2021) · Elsevier eBooks · doi:10.1016/b978-0-323-65399-2.00023-1 · Cited by 1
Wirkung von Endokrinen Disruptoren auf die Tibiametaphyse der ovarektomierten Sprague Dawley Ratte
Vossmann, V. (2011) · eDiss (Georg-August-Universität Göttingen) · doi:10.53846/goediss-1076
Gagné, L., & Maizes, V. (2012) · Elsevier eBooks · doi:10.1016/b978-1-4377-1793-8.00037-6
D'Erasmo, E., & Romagnoli, E. (2009) · Springer eBooks · doi:10.1007/978-88-470-1357-5_6
Osteotropic cytokines mediate human osteoblast-like cell eicosanoid production
Grover, A. (2005) · The Research Repository @ WVU (West Virginia University) · doi:10.33915/etd.4151
“The most significant systemic hormone in regards to maintaining normal bone turnover is estrogen (Pacifici, 1996; Pacifici, 1998).”
BackgroundMarsh, C. A. (2022) · IntechOpen eBooks · doi:10.5772/intechopen.100987
To Study the Impact of Socioeconomic Status on Bone Mineral Density Among South Indian Women
Gladia, R., Ashrin, T., & Paul, J. (2023) · International Journal of Medical and Exercise Science · doi:10.36678/ijmaes.2023.v09i01.002
Evaluation of Thyroid Function of HIV Patients in Umunze, Anambra State, Nigeria
Ukodei, F. U., Nnamah, N., Onuegbu, A. J., Nwako, I. C., Ihim, A. C., Nnamdi, C. J., Nnodiogu, N. J., Ugwu, L. U., & Ekeh, B. (2023) · Asian Journal of Medicine and Health · doi:10.9734/ajmah/2023/v21i11916
“Immune reconstitution (IR) can be defined as an increased CD4+ count above 200cells/mm 3 in subjects who previously had CD4+ counts lower than 100 – 200 cells/mm 3” [4].”
Osteoporosis and Periodontitis: The Bi-Directional Link
Dhande, S. R. (2022) · Clinical Orthopaedics and Trauma Care · doi:10.31579/2694-0248/028
Osteoporoz ve Periodontal Hastalıklar Arasındaki İlişki Üzerine Derleme
Karaaslan, R., Bağış, N., & Fentoğlu, Ö. (2024) · Süleyman Demirel Üniversitesi Sağlık Bilimleri Dergisi · doi:10.22312/sdusbed.1398573
Lipid Mediators and Bone Metabolism
Hikiji, H. (2010) · The Journal of the Kyushu Dental Society · doi:10.2504/kds.64.59
Interleukin-3 as a Potential Bone Anabolic Agent in treating Postmenopausal OsteoporosisPreprint
Piprode, V., Behera, S., Karhade, J., Pandey, G., Prasad, A., Ezhuthachan, K., & Wani, M. R. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.07.12.664485
Liu, X., Zhang, L., Wei, X., & Gao, B. (2025) · Journal of Visualized Experiments · doi:10.3791/68502
Pathophysiology, prevention and treatment of age-related osteoporosis in women
Kassem, M. S., & Brixen, K. (2007) · Springer eBooks · doi:10.1007/1-4020-5058-5_6
“E deficiency has been shown to increase the production of osteoclast-activating cytokines (IL-1, TNF-� , IL-6) and E treatment led to the inhibition of their production ( Pacifici, 1996 ).”
BackgroundSalimi, M., Khanzadeh, M., Nabipoorashrafi, S. A., Seyedi, S. A., Yaghoobpoor, S., Brismée, J.-M., Lucke-Wold, B., Ebadi, M., Ghaedi, A., Kumar, V. S., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26691232
Der Einfluss von Psoriasis vulgaris auf Serummarker des Knochenstoffwechsels: P1NP und CTX-I
Kynast, T. (2020) · Qucosa (Saxon State and University Library Dresden)
Liang, A., Gong, N., Li, S., Lv, W., & Ji, Y. (2026) · Scientific Reports · doi:10.1038/s41598-026-61654-9
Risk factors for falls among older adults in China: a cross-sectional study
Lei, T., & Li, D. (2026) · BMC Public Health · doi:10.1186/s12889-026-26784-9
Elucidating the Role of Extracellular Vesicles during Spinal Development
Aksamit, S. (2022) · TSpace (University of Toronto)
Jin, L., Bian, X., Zhang, G., Zhu, J., Li, X., & Yang, D. (2026) · Frontiers in Microbiology · doi:10.3389/fmicb.2026.1768890
“It is well established that TNF-α and IL-1 β disrupt skeletal homeostasis by potently stimulating osteoclast-mediated bone resorption while simultaneously inhibiting osteoblast-driven bone formation (Graves et al., 2011; Xu et al., 2023; Pacifici, 1996).”
Marchadier, A. (2011) · theses.fr (ABES) · doi:10.70675/8cc7fa67zd577z48d4z9e67zee3331325c34 · Cited by 3
Cakina, S., Sevinc-Postacı, E., Pek, E., Karabıyık, B., & Beyazıt, F. (2026) · Nigerian Journal of Clinical Practice · doi:10.4103/njcp.njcp_511_25
Zhang, Y., Min, L., Zheng, C., Chen, W., Wang, S., & ZHANG, Y. (2026) · Poultry Science · doi:10.1016/j.psj.2026.107170 · Cited by 1
“E 2 has an effect on bone turnover (Xie et al., 2011), and its deficiency led to increased bone turnover and increased osteoclastic bone resorption owing to enhanced production of a number of proinflammatory and osteoclastogenic cytokines (Pacifici, 1996).”
Bowman, L. C., Allaway, H. C. M., Thomas, P. K., & Lau, A. G. (2026) · Springer eBooks · doi:10.1007/978-3-032-10745-9_15
Koerner, J. D., Ng, M. K., Dalton, J., Eichbaum, Y. K., Banko, S. J., Vaccaro, A. R., Markova, D., & Kepler, C. K. (2026) · The Spine Journal · doi:10.1016/j.spinee.2026.07.012
Graves’ disease and bone mineral density: a meta-analysis and UK Biobank
Wu, M., Wang, J., Lu, Y., Yuan, M., Ji, J., Liang, J., Cui, J., Wang, H., Xu, H., Liu, T., et al. (2026) · Frontiers in Endocrinology · doi:10.3389/fendo.2026.1794055
Ianiero, M. A. (2025) · Brock University Digital Repository (Brock University)
Grzechowiak, M., Purpura, A. A., Przybylska, Z., Rolski, W., Michalska, P., Przystaś, B., Hobot, M. P., Dobosz, G. P., & Podeszwa, S. (2026) · International Journal of Innovative Technologies in Social Science · doi:10.31435/ijitss.2(50).2026.5579
“Clinical evidence increasingly supports the existence of a statistically significant synergistic effect when high-magnitude mechanical loading is coupled with pharmacological estrogen replacement, surpassing the efficacy of either intervention as a monotherapy [6, 7].”
Fracture healing: from molecular and cellular mechanisms to therapeutic strategies
Staubli, F., ten Ham, R. M. T., Bergsma, J. E., Gawlitta, D., & Man, K. (2026) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-026-02967-z · Cited by 2
“165 – 167 Estrogen de fi ciency, whether postmenopausal or hypogonadal, increases oxidative stress and NF-κ B activity, elevates TNF, IL-1, and IL-6, impairs osteoblast and stromal-cell function, and promotes osteoclastogenesis.”
Aging of the Human Skeleton and its Contribution to Osteoporotic Fractures
Kassem, M. S., Brixen, K., & Mosekilde, L. (2003) · Springer eBooks · doi:10.1007/978-94-017-0673-5_5
Metadata
- Authors
- Pacifici, R.
- Affiliations
- Washington University in St. Louis (US)
- Corresponding author
- Pacifici, Roberto
- ORCID
- Pacifici, Roberto
- Venue
- Journal of Bone and Mineral Research
- Publisher
- Oxford University Press (OUP)
- Published
- 1996-08-01
- Volume
- 11
- Issue
- 8
- Pages
- 1043-1051
- ISSN
- 0884-0431 (ISSN-L)
- 1523-4681
- OpenAlex
- W2110993073
- Cited by
- 741
- References
- 90
- Citations by year
- 2026: 11 · 2025: 13 · 2024: 15 · 2023: 20 · 2022: 20 · 2021: 24 · 2020: 20 · 2019: 26 · 2018: 30 · 2017: 15 · 2016: 19 · 2015: 31 · 2014: 29 · 2013: 22 · 2012: 28
- FWCI
- 2.44
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- academic.oup.com/journals/pages/open_access/funder_policies/chorus/standard_publication_model (vor)
- Locations
- Journal of Bone and Mineral Research (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health (5r01ag013534-04)
- National Institute on Aging (AG 13534)
- National Institute of Arthritis and Musculoskeletal and Skin Diseases (R01AR041412, AR41412)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Bone Metabolism and Diseases
- Health Sciences › Medicine › Orthopedics and Sports Medicine › Bone health and osteoporosis research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Endocrinology › Estrogen and related hormone effects
- Keywords
- postmenopausal osteoporosis, estrogen deficiency, cytokines, interleukin-1, TNF-α, bone resorption, osteoclastogenesis, osteoclast apoptosis, bone marrow, cytokine synergy, estrogen withdrawal, cytokine inhibitors
- MeSH terms
- Animals, Bone and Bones, Bone Resorption, Estrogens, Female, Humans, Menopause, Osteoporosis, Postmenopausal, Estrogen Replacement Therapy, Cytokines
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.